Data and Documentation
Open Data Policy
FAQ
EN
DE
FR
Suchbegriff
Advanced search
Publication
Back to overview
Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry.
Type of publication
Peer-reviewed
Publikationsform
Original article (peer-reviewed)
Author
Brandenberg Oliver F, Magnus Carsten, Rusert Peter, Regoes Roland R, Trkola Alexandra,
Project
The role of humoral immunity in HIV infection - Understanding broadly neutralizing antibody evolution
Show all
Original article (peer-reviewed)
Journal
PLoS pathogens
Volume (Issue)
11(1)
Page(s)
1004595 - 1004595
Title of proceedings
PLoS pathogens
DOI
10.1371/journal.ppat.1004595
Open Access
URL
http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004595
Type of Open Access
Website
Abstract
HIV-1 enters target cells by virtue of envelope glycoprotein trimers that are incorporated at low density in the viral membrane. How many trimers are required to interact with target cell receptors to mediate virus entry, the HIV entry stoichiometry, still awaits clarification. Here, we provide estimates of the HIV entry stoichiometry utilizing a combined approach of experimental analyses and mathematical modeling. We demonstrate that divergent HIV strains differ in their stoichiometry of entry and require between 1 to 7 trimers, with most strains depending on 2 to 3 trimers to complete infection. Envelope modifications that perturb trimer structure lead to an increase in the entry stoichiometry, as did naturally occurring antibody or entry inhibitor escape mutations. Highlighting the physiological relevance of our findings, a high entry stoichiometry correlated with low virus infectivity and slow virus entry kinetics. The entry stoichiometry therefore directly influences HIV transmission, as trimer number requirements will dictate the infectivity of virus populations and efficacy of neutralizing antibodies. Thereby our results render consideration of stoichiometric concepts relevant for developing antibody-based vaccines and therapeutics against HIV.
-